What is Kite Pharma's stock symbol?
Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."
Where is Kite Pharma's stock going? Where will Kite Pharma's stock price be in 2017?
19 brokerages have issued 1-year target prices for Kite Pharma's shares. Their predictions range from $46.00 to $80.00. On average, they expect Kite Pharma's stock price to reach $70.07 in the next year.
When will Kite Pharma announce their earnings?
Kite Pharma is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Kite Pharma stock?
Here are some recent quotes from research analysts about Kite Pharma stock:
According to Zacks Investment Research, "Kite Pharma is focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer. Kite Pharma continues to progress with its pipeline and initiated a rolling submission of the BLA for KTE-C19, its lead pipeline candidate, for a broader label for aggressive NHL in Dec 2016. KTE-C19 looks well poised for launch in 2017. Moreover, a number of key data readouts are expected in 2017. Loss estimates have remained stable ahead of the company’s Q4 results. The company has a mixed record of earnings surprises in recent quarters. However, with no approved product yet in its portfolio, any setback in the development/regulatory process for KTE-C19 would weigh heavily on the stock. Moreover, there are several other companies working to bring innovative immuno-oncology treatments to market." (2/8/2017)
- Wedbush analysts commented, "KITE is poised to complete submission of the first BLA for a CAR-T therapy, but we believe slow adoption of the new treatment modality may blunt its first mover advantage, as CAR-T competition matures and treatment strategies evolve to address safety and efficacy challenges." (2/1/2017)
Jefferies Group LLC analysts commented, "Recently, a debate has arisen over pot’l Zuma-1 efficacy differences across autologous stem cell transplant (ASCT)-relapsed and refractory pts due to semantics around the word relapsed". We believe little distinction has been given to the ASCT-relapsed group within the larger relapsed population with the perception that ASCT-relapsed pts are healthier than refractory pts." (11/23/2016)
Canaccord Genuity analysts commented, "BeiGene presented updated clinical data for its BTK inhibitor BGB-3111 in patients with Waldenström’s Macroglobulinemia (WM) at the International Workshop on Waldenström’s Macroglobulinemia and Symposium on Advances in Multiple Myeloma (IWWM-9) in Amsterdam, the Netherlands." (10/7/2016)
Barclays PLC analysts commented, "While we need to wait for clarity on durability, (doctors would like to see a med of ~9+ months), based on the Ph1 ZUMA patients, CRs at 3 months appear to be durable out to 9 months, which is encouraging. It will also be important to see CR rates in both chemo-refractory vs. relapse after stem cell transplant (SCT) (the prior being the higher hurdle), however in our view any differences, unless profound, would be unlikely to prevent approval in both patient settings," (9/27/2016)
Who owns Kite Pharma stock?
Kite Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.94%), Menora Mivtachim Holdings LTD. (2.52%), FMR LLC (1.81%), Frontier Capital Management Co. LLC (0.94%), Capital Guardian Trust Co. (0.93%) and First Republic Investment Management Inc. (0.78%). Company insiders that own Kite Pharma stock include Arie Belldegrun, Cynthia M Butitta, David D Chang, Helen Susan Kim, Jeffrey Wiezorek, Marc Better, Margo R Roberts, Ran Nussbaum, Rizwana F Sproule, Roy Doumani and Shawn Tomasello.
Who sold Kite Pharma stock? Who is selling Kite Pharma stock?
Kite Pharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Eventide Asset Management LLC, Raymond James Financial Services Advisors Inc., Allianz Asset Management AG, Capital Guardian Trust Co., Guggenheim Capital LLC and Asset Management One Co. Ltd.. Company insiders that have sold Kite Pharma stock in the last year include Arie Belldegrun, Cynthia M Butitta, David D Chang, Helen Susan Kim, Jeffrey Wiezorek, Margo R Roberts, Rizwana F Sproule, Roy Doumani and Shawn Tomasello.
Who bought Kite Pharma stock? Who is buying Kite Pharma stock?
Kite Pharma's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Deerfield Management Co., Menora Mivtachim Holdings LTD., Frontier Capital Management Co. LLC, Pinnacle Associates Ltd., ARK Investment Management LLC, First Republic Investment Management Inc. and Russell Investments Group Ltd..
How do I buy Kite Pharma stock?
Shares of Kite Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Kite Pharma stock cost?
One share of Kite Pharma stock can currently be purchased for approximately $53.68.